[AZN] Astrazeneca PLC


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 27.31 Change: 0.14 (0.5%)
Ext. hours: Change: 0 (0%)

chart AZN

Refresh chart

Strongest Trends Summary For AZN

AZN is in the long-term up 40% in 2 years and up 44% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS3.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y156.85% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E9.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-2.39 B Cash From Investing Activities-1.23 B Cash From Operating Activities1.01 B Gross Profit5.3 B
Net Profit697 M Operating Profit923 M Total Assets55.17 B Total Current Assets13.81 B
Total Current Liabilities16.15 B Total Debt11.01 B Total Liabilities36.89 B Total Revenue6.31 B
Technical Data
High 52 week41.49 Low 52 week31.22 Last close40.2 Last change-0.07%
RSI67.88 Average true range0.92 Beta0.65 Volume2.88 M
Simple moving average 20 days1.12% Simple moving average 50 days3.01% Simple moving average 200 days9.39%
Performance Data
Performance Week-2.9% Performance Month6.18% Performance Quart4.96% Performance Half8.53%
Performance Year22.15% Performance Year-to-date19.09% Volatility daily1.39% Volatility weekly3.11%
Volatility monthly6.38% Volatility yearly22.09% Relative Volume389.21% Average Volume4.23 M
New High New Low


2019-06-15 07:00:00 | CALQUENCE® acalabrutinib Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

2019-06-14 18:00:05 | Is AstraZeneca plc AZN A Good Stock To Buy?

2019-06-14 08:42:12 | Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

2019-06-14 07:00:00 | LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis

2019-06-13 09:31:01 | Keytruda & 4 Other Reasons to Invest in Merck's MRK Stock

2019-06-10 09:57:01 | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

2019-06-10 08:00:00 | FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

2019-06-07 11:53:36 | New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

2019-06-07 11:04:03 | AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

2019-06-07 10:21:02 | Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

2019-06-06 09:09:01 | Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

2019-06-05 15:11:07 | Cancer-Fighting Stocks & ETF: What You Need to Know

2019-06-05 12:21:17 | How Merck reached new ground in the fight against cancer

2019-06-05 09:50:01 | Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

2019-06-05 09:09:01 | Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

2019-06-03 20:17:46 | PRESS DIGEST- British Business - June 4

2019-06-03 15:14:24 | AstraZeneca searches for successor to Chairman Johansson - Sky News

2019-06-03 14:46:06 | Why Cancer-Fighting Stocks & ETFs Are Soaring

2019-06-03 10:42:02 | AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer

2019-06-03 04:11:24 | Opening Quote: Kier has some nasty news for shareholders

2019-06-02 22:30:34 | PRESS DIGEST- Financial Times - June 3

2019-06-02 13:10:08 | Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

2019-06-02 09:00:00 | IMFINZI® Durvalumab is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer

2019-06-02 07:30:00 | Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

2019-06-02 00:42:54 | AstraZeneca reports encouraging results for early-stage cancer treatments

2019-05-31 11:25:00 | Why Inovio Pharmaceuticals Stock Is Sinking Today

2019-05-29 15:29:07 | Merck MRK Up This Year So Far: Will the Momentum Continue?

2019-05-29 10:34:02 | Allergan's AGN Vraylar Gets FDA Nod for Bipolar Depression

2019-05-28 18:19:00 | Inovio Pharma stock slips as AstraZeneca unit scales back agreement

2019-05-28 12:29:03 | Gaithersburg’s Viela Bio strikes $220M deal with Chinese drug company

2019-05-28 00:50:00 | Tesla, General Motors, Alibaba, and More: Why These Stocks Are in the Spotlight

2019-05-27 10:20:02 | Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy

2019-05-22 07:00:00 | Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide

2019-05-21 02:27:58 | Despite Its High P/E Ratio, Is AstraZeneca PLC LON:AZN Still Undervalued?

2019-05-20 08:00:00 | FASENRA® benralizumab reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma

2019-05-17 09:05:01 | Rigel Initiates Enrollment in Pivotal Blood Disorder Study

2019-05-16 08:00:00 | AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

2019-05-15 09:07:00 | 3 Top Diabetes Stocks to Watch in May

2019-05-14 11:51:22 | AstraZeneca Needs New Breast Cancer Drug to be Blockbuster

2019-05-11 02:51:06 | AVEO Pharmaceuticals AVEO Q1 Earnings & Revenues Miss Mark

2019-05-10 15:29:07 | AVEO Pharmaceuticals AVEO Q1 Earnings & Revenues Miss Mark

2019-05-10 10:21:02 | Inovio INO Q1 Earnings & Revenues Fall Short of Estimates

2019-05-10 07:34:11 | Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

2019-05-09 01:30:03 | AstraZeneca Gets an $8 Billion Punishment

2019-05-08 09:46:01 | Clovis CLVS Q1 Earnings Top Estimates, Rubraca Sales Strong

2019-05-08 07:00:00 | AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer

2019-05-07 10:53:02 | Guardant Health GH to Report Q1 Earnings: What's in Store?

2019-05-03 09:00:00 | Change Makers Across the Oncology Community Recognized at 2019 Cancer Community C2 Awards

2019-05-03 08:36:12 | Ironwood IRWD Q1 Earnings & Revenues Miss, Shares Fall

2019-05-02 15:50:00 | Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices